Promising Biomarker Identified for Early Alzheimer's Disease Detection: miR-519a-3p

Researchers have uncovered new insights into the molecular changes associated with Alzheimer's disease (AD), identifying a specific microRNA (miRNA), miR-519a-3p, that could serve as a biomarker for early detection of the disease. miRNAs are known for their stability in biofluids, presenting an advantageous target for early diagnosis, crucial for effective intervention before the onset of cognitive impairment.

A collaborative research team, including scientists from prominent Spanish institutions such as the Institute for Bioengineering of Catalonia and the University of Barcelona, has published their findings in the journal BBA - Molecular Basis of Disease. They have scrutinized the role of miR-519a-3p in regulating cellular prion protein (PrPC) during AD progression – a protein whose dysfunction is noted in prion diseases and implicated in AD. The results suggest that miR-519a-3p may serve as an indicator of AD in its asymptomatic stages.

Their multifaceted approach involved cross-studying up-regulated miRNAs with in silico identification of those targeting the PRNP gene, responsible for encoding PrPC. Subsequently, the researchers validated the effect of miR-519a-3p on prion protein expression through in vitro experiments. They observed that increased miR-519a-3p significantly correlated with a reduction in PrPC levels, which aligns with disease progression. Importantly, miR-519a-3p was found to be uniquely elevated in AD samples across all disease stages, suggesting its potential as a preclinical diagnostic biomarker.

The researchers demonstrated that miR-519a-3p does not result in PRNP mRNA degradation, implying a translational repression mechanism. Additionally, the team examined cerebral samples from individuals at different stages of AD, discovering increased miR-519a-3p expression even during the earliest, asymptomatic phases. Analysis of samples from other neurodegenerative diseases showed that the elevated levels of miR-519a-3p are specific to AD, bolstering its candidacy as a biomarker.

This discovery is particularly crucial as current methods for AD diagnosis often occur too late for therapeutic interventions to be as effective. Existing blood-based biomarkers are unable to detect the preclinical phase of the disease.

The study's conclusion points to the probability that miR-519a-3p can be used to identify patients silently undergoing the initial stages of AD, facilitating earlier and potentially more successful treatment regimens. The researchers propose further investigation into the clinical application of miR-519a-3p, including prospective studies analyzing blood-derived samples and correlating miRNA levels with clinical outcomes.

For more details regarding this exciting discovery, readers can access the full study in the BBA - Molecular Basis of Disease journal via the following link: https://doi.org/10.1016/j.bbadis.2024.167187.

Built with the help of Buoy Health.